Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Unverricht-Lundborg Disease
NCT03351569Phase 3Unknown
- Sponsor
- ASST Mantova
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Biologic
01
Overview
Phase 3, randomised, double-blind trial of polyvalent human immunoglobulin in Unverricht-Lundborg disease (ULD) (2 arms), sponsored by ASST Mantova. Primary endpoint: Improvement of Action Myoclonus (UMRS Section 4) at 1 year. Status: unknown.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Unverricht-Lundborg disease (ULD)
Beyond the preview
Go deeper on NCT03351569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351569.